Analysis of relief-of-cough in patients with idiopathic pulmonary fibrosis treated with oral nalbuphine extended release

This study analyzed the effect of nalbuphine extended-release tablets versus placebo for the relief of cough in 38 patients with idiopathic pulmonary fibrosis who participated in a Phase 2a study. Cough relief was analyzed by comparing 24-hour mean cough frequency data — collected using the Vitalograph VitaloJAK digital cough monitor — at baseline and after 21 days of treatment.